CARMELINA-elderly-analysis
CARMELINA ® subgroup analysis supports long-term cardiovascular and renal safety of linagliptin in older people with type 2 diabetes Linagliptin did not increase the risk of adverse cardiovascular events, hospitalization for heart failure or adverse kidney events compared with placebo in older people with type 2 diabetes in a prespecified subgroup analysis of the CARMELINA ® cardiovascular outcome trial1In addition, linagliptin did not increase the risk of hypoglycemia compared with placebo in this population1
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | Research | Urology & Nephrology